Anlotinib dihydrochloride is in phase II/III clinical trials for the treatment of metastatic colorectal cancer and advanced gastric adenocarcinoma. The compound was co-developed by CTTQ Pharmaceutical and Advenchen Laboratory.
Cancer Research and Antivirals
|Formula||C23H22FN3O3 • 2HCl|
Send us your enquiry for Anlotinib Dihydrochloride. We offer custom pack sizes at special prices. We aim to respond to your enquiry within 24 hours.
We value your input so if you have suggestions regarding new applications for Anlotinib Dihydrochloride email us and we will include your contribution on the website.